Literature DB >> 29554350

NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.

Ernest Hawk1,2, Karen Colbert Maresso1, Powel Brown1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29554350      PMCID： PMC6136929          DOI： 10.1093/jnci/djy049

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

1.  Celecoxib for the prevention of sporadic colorectal adenomas.

Authors:  Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

2.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Authors:  Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

3.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors:  Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.

Authors: 
Journal:  Contemp Clin Trials       Date:  2013-10-07       Impact factor: 2.226

Review 5.  Role of Aspirin in Breast Cancer Survival.

Authors:  Wendy Y Chen; Michelle D Holmes
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

6.  Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.

Authors:  Judith-Anne W Chapman; Daniel Meng; Lois Shepherd; Wendy Parulekar; James N Ingle; Hyman B Muss; Michael Palmer; Changhong Yu; Paul E Goss
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

7.  Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Authors:  Paul E Goss; James N Ingle; Kathleen I Pritchard; Matthew J Ellis; George W Sledge; G Thomas Budd; Manuela Rabaglio; Rafat H Ansari; David B Johnson; Richard Tozer; David P D'Souza; Haji Chalchal; Silvana Spadafora; Vered Stearns; Edith A Perez; Pedro E R Liedke; Istvan Lang; Catherine Elliott; Karen A Gelmon; Judy-Anne W Chapman; Lois E Shepherd
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

8.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo
Journal:  Ann Intern Med       Date:  2016-04-12       Impact factor: 25.391

9.  ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.

Authors:  David A Drew; Samantha M Chin; Katherine K Gilpin; Melanie Parziale; Emily Pond; Madeline M Schuck; Kathleen Stewart; Meaghan Flagg; Crystal A Rawlings; Vadim Backman; Peter J Carolan; Daniel C Chung; Francis P Colizzo; Matthew Freedman; Manish Gala; John J Garber; Curtis Huttenhower; Dmitriy Kedrin; Hamed Khalili; Douglas S Kwon; Sanford D Markowitz; Ginger L Milne; Norman S Nishioka; James M Richter; Hemant K Roy; Kyle Staller; Molin Wang; Andrew T Chan
Journal:  Trials       Date:  2017-02-01       Impact factor: 2.279
  9 in total
  1 in total

1.  Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Authors:  Anne-Sophie Hamy; Sandrine Tury; Xiaofei Wang; Junheng Gao; Jean-Yves Pierga; Sylvie Giacchetti; Etienne Brain; Barbara Pistilli; Michel Marty; Marc Espié; Gabriel Benchimol; Enora Laas; Marick Laé; Bernard Asselain; Brice Aouchiche; Martin Edelman; Fabien Reyal
Journal:  J Clin Oncol       Date:  2019-01-31       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.